DK3649152T3 - ROR1-antistoffer - Google Patents
ROR1-antistofferInfo
- Publication number
- DK3649152T3 DK3649152T3 DK18742575.6T DK18742575T DK3649152T3 DK 3649152 T3 DK3649152 T3 DK 3649152T3 DK 18742575 T DK18742575 T DK 18742575T DK 3649152 T3 DK3649152 T3 DK 3649152T3
- Authority
- DK
- Denmark
- Prior art keywords
- ror1 antibodies
- ror1
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1710835.8A GB201710835D0 (en) | 2017-07-05 | 2017-07-05 | ROR1 Antibodies |
| PCT/GB2018/051914 WO2019008377A1 (en) | 2017-07-05 | 2018-07-05 | ANTIBODY ROR1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3649152T3 true DK3649152T3 (da) | 2025-11-10 |
Family
ID=59592560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18742575.6T DK3649152T3 (da) | 2017-07-05 | 2018-07-05 | ROR1-antistoffer |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11466083B2 (enExample) |
| EP (1) | EP3649152B1 (enExample) |
| JP (1) | JP7242573B2 (enExample) |
| CN (1) | CN110891973B (enExample) |
| AU (1) | AU2018297630B2 (enExample) |
| CA (1) | CA3068196A1 (enExample) |
| DK (1) | DK3649152T3 (enExample) |
| ES (1) | ES3048696T3 (enExample) |
| GB (1) | GB201710835D0 (enExample) |
| MX (1) | MX2019015348A (enExample) |
| WO (1) | WO2019008377A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| US20230416942A1 (en) * | 2020-08-21 | 2023-12-28 | Yale University | Nanobody Compositions and Methods of Use of the Same |
| IL300760A (en) * | 2020-08-24 | 2023-04-01 | Epimab Biotherapeutics Hk Ltd | Anti-ROR1 antibodies and related bispecific binding proteins |
| EP4209509A4 (en) * | 2020-09-03 | 2025-03-19 | Harbour Biomed (Shanghai) Co., Ltd | ROR1-TARGETTING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION THEREOF AND USE THEREOF |
| JP2023550628A (ja) * | 2020-11-23 | 2023-12-04 | スカウト バイオ， インコーポレイテッド | 抗原結合分子およびその使用 |
| WO2022182562A1 (en) * | 2021-02-23 | 2022-09-01 | BioLegend, Inc. | ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| US20240309116A1 (en) * | 2021-07-23 | 2024-09-19 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against ror1 and uses thereof |
| CN113956359B (zh) * | 2021-10-29 | 2022-09-16 | 叶鑫淼 | 一种抗体及其在抗肿瘤中的应用 |
| CN118302448A (zh) * | 2021-12-28 | 2024-07-05 | 江苏恒瑞医药股份有限公司 | 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途 |
| PE20251274A1 (es) * | 2022-03-09 | 2025-05-14 | Sanyou Biopharmaceuticals Co Ltd | Molecula de union dirigida a ror1 y uso de la misma |
| CN119604529A (zh) * | 2022-07-11 | 2025-03-11 | 翰森生物有限责任公司 | 抗体、其抗原结合片段及其药物用途 |
| CN116836286A (zh) * | 2022-09-07 | 2023-10-03 | 中国科学院合肥物质科学研究院 | 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用 |
| CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物（武汉）科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
| CN118440200B (zh) * | 2023-04-21 | 2025-05-16 | 星奕昂(上海)生物科技有限公司 | 靶向ror1的抗体及其应用 |
| AU2024331841A1 (en) * | 2023-08-31 | 2026-03-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| WO2007146957A2 (en) | 2006-06-13 | 2007-12-21 | Irm Llc | Ror1 as a therapeutic target for lung cancer |
| US9316646B2 (en) * | 2009-04-23 | 2016-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
| WO2011054007A1 (en) * | 2009-11-02 | 2011-05-05 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
| US9150647B2 (en) | 2009-12-18 | 2015-10-06 | Kancera Ab | Biological inhibitors of ROR1 capable of inducing cell death |
| US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
| EP2646469B1 (en) | 2010-12-01 | 2017-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Chimeric rabbit/human ror1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| US10752684B2 (en) * | 2014-07-29 | 2020-08-25 | Cellectis | ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy |
| WO2016016343A1 (en) | 2014-07-31 | 2016-02-04 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
| AU2015313268B2 (en) | 2014-09-08 | 2018-12-20 | National Cancer Center | Cancer-cell-specific antibody, anticancer agent, and cancer testing method |
| JP2017536341A (ja) | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| US20160208018A1 (en) * | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| EP3253754B1 (en) | 2015-02-02 | 2021-03-31 | Kancera AB | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity |
| HK1253507A1 (zh) * | 2015-05-18 | 2019-06-21 | Eureka Therapeutics, Inc. | 抗 ror1 抗体 |
| CN108137669B (zh) | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
| CA3001941A1 (en) | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-ror1 antibodies |
| MX2018008926A (es) | 2016-01-20 | 2019-01-10 | Scripps Research Inst | Composiciones de anticuerpo contra ror1 y métodos relacionados. |
| CA3011419A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Biotech, Inc. | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same |
| AR108034A1 (es) | 2016-02-17 | 2018-07-11 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| US11008318B2 (en) | 2016-07-11 | 2021-05-18 | Kancera Ab | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity |
| US20200338210A1 (en) | 2016-12-22 | 2020-10-29 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| AU2018271872A1 (en) | 2017-05-23 | 2019-12-12 | Dragonfly Therapeutics, Inc. | A protein binding NKG2D, CD16 and ROR1 or ROR2 |
| TWI804499B (zh) | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1抗體免疫接合物 |
| EP3645741A4 (en) | 2017-06-25 | 2021-08-25 | Systimmune, Inc. | ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| US20210139579A1 (en) | 2017-07-20 | 2021-05-13 | Nbe-Therapeutics Ag | Multispecific antibody product that binds to different ror1 epitopes |
| KR20230008269A (ko) | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| CN117756946A (zh) | 2017-11-03 | 2024-03-26 | 莱蒂恩技术公司 | 用于用抗ror1免疫治疗来治疗癌症的组合物和方法 |
| GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2019225777A1 (ko) | 2018-05-23 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-ror1 항체 및 그 용도 |
-
2017
- 2017-07-05 GB GBGB1710835.8A patent/GB201710835D0/en not_active Ceased
-
2018
- 2018-07-05 MX MX2019015348A patent/MX2019015348A/es unknown
- 2018-07-05 WO PCT/GB2018/051914 patent/WO2019008377A1/en not_active Ceased
- 2018-07-05 DK DK18742575.6T patent/DK3649152T3/da active
- 2018-07-05 JP JP2019572456A patent/JP7242573B2/ja active Active
- 2018-07-05 CN CN201880045361.4A patent/CN110891973B/zh active Active
- 2018-07-05 CA CA3068196A patent/CA3068196A1/en active Pending
- 2018-07-05 EP EP18742575.6A patent/EP3649152B1/en active Active
- 2018-07-05 ES ES18742575T patent/ES3048696T3/es active Active
- 2018-07-05 AU AU2018297630A patent/AU2018297630B2/en active Active
- 2018-07-05 US US16/628,512 patent/US11466083B2/en active Active
-
2022
- 2022-07-21 US US17/869,872 patent/US20230220073A1/en not_active Abandoned
-
2024
- 2024-08-26 US US18/815,603 patent/US20250066472A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11466083B2 (en) | 2022-10-11 |
| US20230220073A1 (en) | 2023-07-13 |
| JP7242573B2 (ja) | 2023-03-20 |
| US20200354448A1 (en) | 2020-11-12 |
| MX2019015348A (es) | 2020-07-20 |
| US20250066472A1 (en) | 2025-02-27 |
| WO2019008377A1 (en) | 2019-01-10 |
| ES3048696T3 (en) | 2025-12-11 |
| EP3649152B1 (en) | 2025-10-08 |
| CN110891973B (zh) | 2023-06-27 |
| AU2018297630A1 (en) | 2020-01-16 |
| CA3068196A1 (en) | 2019-01-10 |
| CN110891973A (zh) | 2020-03-17 |
| JP2020530272A (ja) | 2020-10-22 |
| GB201710835D0 (en) | 2017-08-16 |
| EP3649152A1 (en) | 2020-05-13 |
| AU2018297630B2 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| HUE060019T2 (hu) | Anti-LAG3 antitestek | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| EP3319984C0 (en) | TAU LINKING ANTIBODIES | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| DE202018003363U8 (de) | Handgelenkssphygmomanometer | |
| IL256099A (en) | Antibody | |
| EP3319983C0 (en) | TAU LINKING ANTIBODIES | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| DK3529269T3 (da) | Antistof-konstruktioner | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| EP3718392A4 (en) | HARVEST MACHINE | |
| GB201710835D0 (en) | ROR1 Antibodies | |
| EP3615678C0 (en) | ANTIBODY SELECTION METHOD | |
| IL257368A (en) | Antibody | |
| DK3452515T3 (da) | Her-2-bindende antistoffer | |
| EP3579879A4 (en) | ANTI-BODY ANTI-KIR3DL1 |